BGS2597

BGS2597 is an investigational **small-molecule** WDR5 inhibitor being developed by BridGene. It was identified and optimized using BridGene's chemoproteomic IMTAC platform and was reported as an improved follow-on compound derived from the earlier hit BGS1989. Mechanistically, BGS2597 inhibits the **WDR5-MLL protein-protein interaction** and suppresses **H3K4 methylation**, consistent with an epigenetic anticancer strategy aimed at disrupting WDR5-dependent chromatin regulatory complexes. Publicly available context supports interest in oncology applications, but no specific clinical-stage indication or approved use has been established from the provided evidence.